K Immonen, M Kauppi, M Hakala. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » AdalimumabAdultAmyloidosis/complicationsAmyloidosis/drug therapyAmyloidosis/metabolismAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntirheumatic Agents/therapeutic useArthritis, Juvenile/complicationsArthritis, Juvenile/drug therapyArthritis, Juvenile/metabolismArthritis, Psoriatic/complicationsArthritis, Psoriatic/drug therapyArthritis, Psoriatic/metabolismArthritis, Rheumatoid/complicationsArthritis, Rheumatoid/drug therapyArthritis, Rheumatoid/metabolismBiopsyFemaleHumansMaleSerum Amyloid A Protein/metabolismSpondylitis, Ankylosing/complicationsSpondylitis, Ankylosing/drug therapySpondylitis, Ankylosing/metabolismSubcutaneous Fat, Abdominal/metabolismSubcutaneous Fat, Abdominal/pathologyTreatment Outcome
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntirheumatic AgentsSerum Amyloid A ProteinAdalimumabtocilizumab
Year: 2011 PMID: 21231814 DOI: 10.3109/03009742.2010.530294
Source DB: PubMed Journal: Scand J Rheumatol ISSN: 0300-9742 Impact factor: 3.641